x
J L E S
Make A Submission

Current Issue

  • Home
  • Current Issue Details

Most Popular

RNA INTERFERENCE AND ITS ROLE IN THE INHIBITION AND CURE OF HIV/AIDS

By: Istiak Mahfuz, Abul Mandal

Key Words: HIV/AIDS, RNA interference, treatments, limitations

JLES-Vol-5-No-P-1-10, December 2010

Abstract

The HIV/AIDS epidemic kills about 2.1 million people around the world every year. Unfortunately, until now attempts to control and diminish further spread of the disorder have resulted in very limited success. Although highly active antiretroviral therapy (HAART) is now available as a treatment option, the rate of its success is limited because of drug resistance. In this context, a more efficient treatment is very much necessary to fight with this fatal disease. The RNA interference (RNAi) can be employed as one of the powerful methods for treatment of the disease as it can effectively silence gene expression in a sequence specific manner. The RNAi-mediated treatment is therefore a promising substitution for therapy of the global epidemic HIV/AIDS in the future. The main objective of this review is to focus on an in-depth analysis of RNAi and the principles underlying RNAi treatment, and it’s also describes the molecular mechanisms of HIV infection, current treatment facilities available to patients as well as therapeutic applications of RNAi along with their limitations as to why the options are inadequate to give a safe and sound cure of HIV/AIDS.

Download cover Download the full paper

Bagasra O, Prilliman K R. 2004. RNA interference: the molecular immune system. J Mol Histol 35(6), 545–553.

Bailes E, Gao F, Bibollet-Ruche F, Courgnaud V, Peeters M, Marx P A, Hahn B H, Sharp P M. 2003. Hybrid Origin of SIV in Chimpanzees. Science 300(5626), p. 1713.

Barichievy S, Saayman S. Arbuthnot P, Weinberg M S. 2009. RNA Interference-Based Gene Expression Strategies Aimed at Sustained Therapeutic Inhibition of HIV. Current Topics Med Chem 9(12), 1065-1078.

Bartel D P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297.

Berkhout B, Brake O. 2009.Towards a durable RNAi gene therapy for HIV-AIDS. Expert Opinion on Biological Therapy 9(2), 161-170.

Berkhout B. 2010. Toward a durable anti-HIV gene therapy based on RNA interference. Ann New York Acad Sci 1175, 3-14. Blankson J N, Persaud D, Siliciano R F. 2002. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 53, 557-593.

Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. 2003, Human immunodeficiency virus type 1 escape from RNA interference. J Virol 77, 11531-11535.

Bukrinsky M I, Haffar O K. 1997. HIV-1 nuclear import: in search of a leader. Frontiers in Bioscience 2, 578–587.

Bukrinsky M I. 2001. HIV Life Cycle and Inherited Coreceptors. Encyclopedia of life sciences & Nature Publishing Group. www.els.net. pp. 1-6.

Buvé A. 2000. HIV/AIDS in Africa: Why so severe, why so heterogeneous? Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, San Francisco, Calif. Abstract S28.

Capodici J, Kariko´ K, Weissman D. 2002. Inhibition of HIV-1 Infection by Small Interfering RNA-Mediated RNA Interference. J Immunol 169, 5196–5201.

Carol A S, Bryan R G W. 2005. RNA interference in biology and disease. Blood 106(3), 787-794.

Chan D, Kim P. 1998. HIV entry and its inhibition. Cell 93(5), 681–684.

Clemens J C, Worby C A, Simonson-Leff N, Muda M, Maehama T, Hemmings B A, Dixon J E. 2000. Use of double-stranded RNA interference in Drosophila cell lines to dissect signal transduction pathways. Proc Natl Acad Sci USA 97, 6499-6503.

Coburn G A, Cullen B R. 2002. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J Virol 76, 9225-9231.

Cohen J. 2002. Why Drugs Can’t Keep HIV Down? Science Now 708, 4-19.

Daneholt B.2006. Advanced Information: RNA interference.

The Nobel Prize in Physiology or Medicine 2006. http://nobelprize.org/nobel_prizes/medicine/laureates/2 006/adv.html.

Das A T, Brummelkamp T R, Westerhout E M, Vink M, Madiredjo M, Bernards R, Berkhout B. 2004. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 78, 2601-2605.

DeGruttola V, Dix L, D’Aquila R, Holder D, Phillips A, Ait- Khaled  M, Baxter  J,  Clevenbergh  P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5, 41-48.

Denning P H. 2000. Is the stage being set for resurgence in the HIV epidemic among men who have sex with men? Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30- February 2, San Francisco, Calif. Abstract S30.

DiGiusto D L, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey S F, Yee J K, Li M, Couture L, Hsu D, Forman S J, .Rossi J J, Zaia J A. 2010. RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma. Sci Transl Med 2(36), 36-43.

Douek D C, Roederer M, Koup R A. 2009. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 60, 471–84.

Dybul M, Fauci A S, Bartlett J G, Kaplan J E, Pau A K. 2002. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 137(5 Pt 2), 381-433.

Engels B M, Hutvagner G. 2006. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Nature Journal, Oncogene 25, 6163–6169.

FHI and CAPRISA. 2010. FHI and the Centre for the AIDS Programme of Research in South Africa. Factsheet: CAPRISA 004 and HIV drug resistance. Research Triangle Park, NC USA.

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello

  1. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabdites elegans. Nature 391, 806-811.

Gao F, Bailes E, Robertson D L, Chen Y, Rodenburg C M, Michael S F, Cummins L B, Arthur L O, Peeters M, Shaw G M, Sharp P M, Hahn B H. 1999. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 397, 436-441.

Gregory R, Chendrimada T, Cooch N, Shiekhattar R. 2005. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 123(4), 631–640.

Hannon G J, Rossi J J. 2004. Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378.

Hannon G J. 2002. RNA interference. Nature 418, 244-251. Hirschel B, Calmy A. 2008. Initial Treatment for HIV

Infection- An Embarrassment of Riches. New England J Medicine, 358(20), 2170-2172.

Hiscott J, Kwon H, Genin P. 2001. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 107(2), 143–151.

HIVSTOP. 2010. Development of an Effective RNA Interference- Based Anti-HIV-1 Therapy Using an SV40-Derived Vector. http://ec.europa.eu/research/health/infectious-diseases/ poverty-diseases/projects/ 139_en.htm.

Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, Crooks G M, Kohn D B, Gregory P D, Holmes M C, Cannon P M. 2010. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nature Biotechnology 28, 839–847.

Homas T, Kuby K. 2007. Immunology. W.H. Freeman and Company, New York.

Irvine D, Zaratiegui M, Tolia N, Goto D, Chitwood D, Vaughn M, Joshua-Tor L, Martienssen R. 2006. Argonaute slicing is required for heterochromatic silencing and spreading. Science 313(5790), 1134–1137.

Jacque J M, Triques K, Stevenson M. 2002. Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438.

Jagannath A, Wood M. 2007. RNA interference based gene therapy for neurological disease. Brief Funct Genomic Proteomic, 6(1), 40-49.

Jia F, Zhang YZ, Liu CM. 2006. A retrovirus-based system to stably silence hepatitis B virus genes by RNA interference. Biotechnol Lett, 28(20), 1679-1685.

Jiang M, Milner J. 2002. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene, 21(39), 6041-6048.

Katz M, Martin J, Roland M. 2000. The San Francisco postexposure prevention program: lessons and future challenges. Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections, January 30-February 2, San Francisco, Calif. Abstract S29.

Kusov Y, Kanda T, Palmenberg A, Sgro J, Gauss-Müller V. 2006. Silencing of Hepatitis A Virus Infection by Small Interfering RNAs. J Virol 80(11), 5599-5610.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti

  1. 1999. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 282, 2220-2226.

Lee N S, Dohjima T, Bauer G, Li H, Li M J, Ehsani A, Salvaterra P, Rossi J. 2002. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat Biotechnol 20, 500-505.

Leonard J N, Schaffer D V. 2005. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther 13, 532-540.

Lindsay M A. 2008. microRNAs and the immune response.

Trends Immunol 29(7), 343-351.

Martinez M A, Clotet B, Este J A. 2002. RNA interference of HIV replication. Trends Immunol 23, 559-561.

Martinez-Picado J, DePasquale, M P, Kartsonis N, Hanna G J, Wong J, Finzi D, Rosenberg E, Gunthard H F, Sutton L, Savara A, Petropoulos C J, Hellmann N, Walker B D, Richman D D, Siliciano R, D’Aquila R T. 2000. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection. Proc Natl Acad Sci 97(20), 10948-10953.

Moatti J P, N’Doye I, Hammer S M, Hale P, Kazatchkine M. 2003. Antiretroviral treatment for HIV infection in developing countries: an attainable new paradigm. Nature Medicine 9, 1449-1452.

Morris K V, Rossi J J. 2006. Lentivirus- Mediated RNA Interference therapy for Human immunodeficiency virus type 1 infection. Hum Gene Ther 17(5), 479-486.

Novina C D, Murray M F, Dykxhoorn D M, Beresford P J, Riess J, Lee S K, Collman R G, Lieberman J, Shankar P, Sharp P A. 2002. siRNA-directed inhibition of HIV- 1 infection. Nat Med 8, 681-686.

Osherovich L. 2010. Zinc-ing differently about HIV. SciBX

3(27). Colleted from the internet: http://www.nature.com/scibx/journal/v3/n27/full/scibx. 2010.814.html.

Palella F J, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, Aschman D J, Holmberg S D. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J 338, 853-860.

Patrick G Y, Scott M H, Martin S H, Michael S S, Mauro S, Charles C J C, Margaret A F, Jose M G, Brian G G, Donna M J, David A K, Julio S G M, Douglas D R, Robert T S, Melanie A T, Stefano V, Paul A V.(2004). Treatment for Adult HIV Infection. JAMA 292, 251-265.

Pedersen I, David M. 2008. microRNAs in the immune response. Cytokine 43(3), 391-394.

Pollard V W, Malim M H. 1998. The HIV-1 Rev protein. Annu Rev Microbiol 52, 491–532.

Rana M T. 2007. Illuminating the silence: understanding the structure and function of small RNAs. Nature Reviews, Molecular Cell Biology 8, 23-36.

Reeves J D, Doms R W. 2002. Human Immunodeficiency Virus Type 2. J Gen Virol 83(6), 1253–1265.

Istiak Mahfuz, Abul Mandal

RNA INTERFERENCE AND ITS ROLE IN THE INHIBITION AND CURE OF HIV/AIDS

JLES-Vol-5-No-P-1-10, December 2010

https://jlescience.com/les-publish/rna-interference-and-its-role-in-the-inhibition-and-cure-of-hiv-aids/

Copyright © 2022
By Authors and Journal of Life and Earth Science (JLES)
https://jlescience.com